生物素A通过线粒体通路和Pi3K/AKT抑制诱导MCF-7乳腺癌细胞的亡
Dianxiu Wang1, Chuyi Zheng2, Bo Chen3
1Department of General Surgery, SiJing Hospital of SongJiang District, Shanghai, China.
Cell biochemistry and function
|November 12, 2024
概括
生物素A有效抑制乳腺癌细胞活力,并触发细胞亡. 这种天然化合物抑制PI3K/Akt通路并调节细胞周期标记物,提供潜在的治疗益处.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌仍然是全球主要的死亡原因.
- 识别具有较少副作用的新型治疗剂至关重要.
- 生物素A是一种天然的异黄,已显示出潜在的抗癌特性.
研究的目的:
- 阐明Biochanin A在乳腺癌中抗癌作用的分子机制.
- 研究生物素A对细胞增殖,细胞亡和关键信号通路的影响.
主要方法:
- 用不同度的生物素A对MCF-7乳腺癌细胞进行了治疗.
- 评估了细胞增殖,反应性氧物种 (ROS) 生成和细胞亡.
- 进行了西斑和PCR阵列分析,以检查蛋白质和基因表达.
主要成果:
- 生物素A显著抑制了MCF-7细胞增殖和诱导了细胞亡.
- 治疗导致ROS的形成增加,并改变了与亡相关的蛋白质的表达 (Bcl-2,Bax,Caspase-3,Caspase-9,cytochrome c).
- 生物素A降低细胞循环调节剂 (环林,CDK) 和上调细胞循环抑制剂 (p21,p27,p53),同时也抑制PI3K/Akt通路.
结论:
- 生物素A通过线粒体通路诱导乳腺癌细胞的亡.
- 抑制PI3K/Akt信号通路和调节细胞循环标记物有助于生物氨酸A的抗癌活性.
- 这些发现强调了生物素A作为乳腺癌治疗的有希望的候选人.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.7K
04:20Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
878
相关概念视频
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
